Get the Stockscreener App
13.98
4.02%
0.54
After Hours:
14.02
0.04
+0.29%
Janux Therapeutics Inc stock is traded at $13.98, with a volume of 2.19M.
It is up +4.02% in the last 24 hours and down -15.32% over the past month.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
See More
Previous Close:
$13.44
Open:
$13.475
24h Volume:
2.19M
Relative Volume:
1.19
Market Cap:
$840.87M
Revenue:
$439.00K
Net Income/Loss:
$-105.64M
P/E Ratio:
-7.7667
EPS:
-1.8
Net Cash Flow:
$-60.70M
1W Performance:
+1.30%
1M Performance:
-15.32%
6M Performance:
-41.65%
1Y Performance:
-75.82%
1-Day Range:
$13.47
$14.30
1-Week Range:
$13.26
$14.30
52-Week Range:
$13.26
$56.89
Janux Therapeutics Inc Stock (JANX) Company Profile
Name
Janux Therapeutics Inc
Sector
Industry
Phone
(858) 751-4493
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
13.98 | 808.39M | 439.00K | -105.64M | -60.70M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-10-25 | Initiated | Stifel | Buy |
| Sep-10-25 | Initiated | Truist | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-11-25 | Initiated | Raymond James | Outperform |
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Dec-03-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-22-24 | Initiated | Leerink Partners | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-06-24 | Initiated | Stifel | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Perform |
| Mar-21-24 | Initiated | BTIG Research | Buy |
| Mar-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-23 | Initiated | Wedbush | Outperform |
| Nov-14-22 | Initiated | William Blair | Outperform |
View All
Janux Therapeutics Inc Stock (JANX) Latest News
Will Janux Therapeutics Inc. stock benefit from infrastructure spendingDividend Growth Stocks & High Return Trading Portfolio - ulpravda.ru
BofA Adjusts Price Target on Janux Therapeutics to $35 From $49, Maintains Buy Rating - MarketScreener
Janux Therapeutics (NASDAQ:JANX) Sets New 12-Month LowWhat's Next? - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Nasdaq 100 Index Biotech Innovator - Kalkine Media
Pre-market Movers: RSLS, STSS, VERO, KTTA... - RTTNews
Andrew Hollman Meyer Sells 1,879 Shares of Janux Therapeutics (NASDAQ:JANX) Stock - MarketBeat
Janux Therapeutics CEO Campbell sells $110k in stock By Investing.com - Investing.com Canada
Janux Therapeutics’ CMO McIver sells $37k in shares - Investing.com
Janux Therapeutics CBO Meyer sells $25,798 in stock By Investing.com - Investing.com Canada
Janux Therapeutics CSO sells $34k in shares - Investing.com India
Maria Dobek, Janux Therapeutics VP, sells $20k in shares By Investing.com - Investing.com UK
Insider Selling: Janux Therapeutics (NASDAQ:JANX) Insider Sells 2,714 Shares of Stock - MarketBeat
Janux Therapeutics (NASDAQ:JANX) CEO David Alan Campbell Sells 8,072 Shares of Stock - MarketBeat
Janux Therapeutics (NASDAQ:JANX) VP Maria Dobek Sells 1,462 Shares - MarketBeat
Janux Therapeutics CSO sells $34k in shares By Investing.com - Investing.com UK
(JANX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Janux Therapeutics’ CMO McIver sells $37k in shares By Investing.com - Investing.com UK
Janux Therapeutics (NASDAQ:JANX) Sets New 52-Week LowHere's What Happened - MarketBeat
Is Janux Therapeutics Inc a good long term investmentEarnings Call Summaries & Exceptional Return Capital - earlytimes.in
Biotech Trio Gets Hammered On Heavy Trading - Finimize
Why Wall Street Sees Big Potential in Janux Therapeutics, Inc. (JANX) - Finviz
Why Wall Street sees big potential in Janux Therapeutics, Inc. (JANX) - MSN
TD Cowen Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: MannKind (MNKD) and Janux Therapeutics Inc (JANX) - The Globe and Mail
What analysts say about Janux Therapeutics Inc stockHead and Shoulders Patterns & High Yield Trading Signals - earlytimes.in
Janux Therapeutics Pipeline Remains on Track as JANX008 Advances, Wedbush Says - marketscreener.com
Janux Completes Phase 1a Dose-escalation In Phase 1 JANX008 Study; Expansion Cohorts To Commence - Nasdaq
Janux completes phase 1a dose-escalation for EGFR cancer drug By Investing.com - Investing.com UK
Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study - New Castle News
Here are the most and least likely M&A targets in biotech, according to Truist - Seeking Alpha
Janux Therapeutics Earnings Notes - Trefis
How Janux Therapeutics Inc. (JANX) Affects Rotational Strategy Timing - Stock Traders Daily
Why Janux Therapeutics Inc. stock is favored by top institutions2025 Buyback Activity & Free Reliable Trade Execution Plans - Улправда
Why Janux Therapeutics Inc. stock remains resilientQuarterly Risk Review & Step-by-Step Trade Execution Guides - Улправда
2 'strong buy' biotech stocks with 208% to 329% upside potential - MSN
Market Rankings: Is Janux Therapeutics Inc. stock supported by strong fundamentalsDay Trade & Verified High Yield Trade Plans - Улправда
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Big Money Moves: Is Janux Therapeutics Inc. stock supported by strong fundamentalsWeekly Profit Summary & Technical Buy Zone Confirmations - Улправда
Janux Therapeutics (NASDAQ:JANX) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Why Janux Therapeutics Inc. stock remains a top recommendationMarket Rally & AI Driven Stock Movement Reports - Улправда
Is Janux Therapeutics Inc. stock a contrarian buyMarket Activity Summary & Daily Chart Pattern Signals - Улправда
Buyout Rumor: Why Janux Therapeutics Inc. stock is favored by top institutionsWeekly Profit Report & Capital Efficient Trade Techniques - Улправда
Barclays Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
Barclays Maintains Janux Therapeutics (JANX) Overweight Recommendation - Nasdaq
Janux Therapeutics (NASDAQ:JANX) Hits New 12-Month LowHere's What Happened - MarketBeat
Squarepoint Ops LLC Raises Stock Position in Janux Therapeutics, Inc. $JANX - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Palmetto Grain Brokerage - Palmetto Grain Brokerage
2 ‘Strong Buy’ Biotech Stocks With 208% to 329% Upside Potential - Barchart.com
Wyckoff Accumulation Phase Possible in National Standard India LimitedBlue Chip Stock Analysis & Low Cost Capital Growth - earlytimes.in
Options Exercise: Janux Executive Sells 16,665 Shares for $501,000 - AOL.com
Janux Therapeutics Inc Stock (JANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):